SniperFx

Archives

  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • September 2022
  • August 2022
  • January 2022
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Bonds
  • Brokers News
  • Crypto
  • Forex
  • Forex Trading
  • News
  • Stocks
  • Technology
  • World
Subscribe
SniperFx SniperFx
SniperFx
  • Latest Updates
  • Bonds
  • Brokers News
  • Crypto
  • Forex
  • Forex Trading
  • Stocks
  • World
  • News

University of Queensland’s COVID vaccine technology finally moves to human trial phase after 2020 false start

  • March 20, 2023

A human trial has been launched into the University of Queensland’s (UQ) second generation COVID vaccine, more than two years after the original technology was abandoned amid patients falsely testing positive to HIV.

Key points:

  • UQ researchers are working to create technology that can be used for multiple viruses
  • The original project was abandoned in 2020 and is now in its second generation
  • Researchers are seeking volunteers to participate in human trials

UQ scientists have re-engineered the molecular clamp technology and need 70 healthy volunteers aged 18 to 50 to test its effectiveness as a COVID vaccine compared to the approved Novavax shot.

Although the trial will assess the technology – dubbed Clamp2 — as a COVID vaccine, the researchers say if it’s successful, it’s more likely to be used to protect people during future pandemics and in jabs for existing viruses, such as respiratory syncytial virus (RSV).

Project leader Keith Chappell said the scientists were working on using the technology to create vaccines for “a range of viruses”.

“Our primary purpose is not to bring another COVID vaccine to market,” Associate Professor Chappell said.

“The vaccines that are out there are working extremely well and keeping a lot of people out of hospitals.

“This isn’t going to be the last time the world faces a pandemic and next time around, we want to … make sure there are doses available as quickly as possible and they’re safe, and they can protect Australians and people around the world.

“If we can show that this technology is safe and that it’s effective, the next time around we can ramp up extremely quickly and get vaccines to the people that need them in an emergency.”

Professor Chappell said he was “extremely confident” in the potential of Clamp2.

“I hope to one day save some lives and produce a vaccine that can make a difference,” he said.

What’s changed since last time?

The original clamp technology contained two fragments of a protein found in HIV, which acted like a chemical bulldog clip, holding together an engineered version of the spike protein found on the surface of SARS-CoV-2, the virus that causes COVID-19.

That worked by allowing the immune system to recognise – and attack – the spike protein, producing protective antibodies.

On its own, the SARS-CoV-2 spike protein is unstable. It needs to be locked into shape to ensure the vaccine produces a robust immune response.

But the molecular clamp used in the original UQ vaccine also resulted in people falsely testing positive to HIV, causing it to be dramatically abandoned.

Professor Chappell said the fragments of protein in HIV had been replaced by a “small amino acid sequence with similar properties” in Clamp2.

He could not reveal more details because of intellectual property protections.

“We had to go right back to square one to define something that had the right properties to be a molecular clamp,” Professor Chappell said.

“We also had to completely redefine how we manufactured this vaccine because we were using a specific purification methodology that would purify the original molecular clamp.

“Not only did we need to change the molecular clamp, we needed to change the purification methodology. We now have that working extremely well.”

The molecular virologist said vaccines using the UQ technology would have benefits over existing technology, once licensed by medicine regulators.

“They’ll be cheaper, they can get to regions of the world that are resource-limited and also have the stability to be able to be shipped around the world without having to be frozen at extremely low temperatures,” Professor Chappell said.

“The biggest benefit in terms of pandemic preparedness is that it can be rapidly scaled up into millions and millions of doses.”

Researchers seeking trial participants

Professor Chappell said volunteers wanted for Clamp2’s first human trial need to have received a COVID vaccine, but not in the past three months.

They also cannot have contracted SARS-CoV-2 in the past three months.

“There are no overnight stays required and participants will be reimbursed for their time,” he said.

Want more local stories?

We’ve got an ABC News homepage for you. Adjust your settings for the right mix of local and national news.

The Coalition for Epidemic Preparedness Innovation (CEPI) is providing up to $8.5 million to support further development of the UQ technology for use in the global response to future disease outbreaks.

Nucleus Network will conduct the trial in Brisbane. Half the participants will be given one dose of the UQ vaccine and the rest will receive Novavax’s COVID shot.

They will be monitored for six months.

admin

Previous Article
  • Bonds

Liam Neeson Reveals Rejecting James Bond’s Role Because Of His Then Girlfriend

  • March 20, 2023
Read More
Next Article
  • Crypto

Beware of fake Arbitrum Airdrops, community warns

  • March 20, 2023
Read More
You May Also Like
Read More
  • News

LG Display flags Q4 turnaround after 5th straight quarterly loss

  • admin
  • July 26, 2023
Federal Reserve Decision
Read More
  • News

Federal Reserve Decision – Expected Pause in June, Potential for July Rate Hike – Date: 13.06.23

  • admin
  • June 13, 2023
NZD USD Reaches Multi Week High Ahead
Read More
  • News
  • Forex Trading

NZD USD Reaches Multi Week High Ahead of US CPI Release – Date: 13.06.23

  • admin
  • June 13, 2023
EUR USD Await FOMC Meeting
Read More
  • Forex
  • News

EUR USD Await FOMC Meeting Irrespective of US CPI Data Commerzbank – Date: 13.06.23

  • admin
  • June 13, 2023
Binance US Counters
Read More
  • Crypto
  • News

Binance US Counters SEC’s Motion to Freeze Funds, Citing Failure of Claims

  • admin
  • June 13, 2023
Exchange Traded Funds
Read More
  • News
  • Forex
  • Forex Trading

Exchange Traded Funds (ETFs): A Comprehensive Guide to Investing and Profit Maximisation

  • admin
  • June 12, 2023
SEC Official
Read More
  • News
  • Crypto

Former SEC Official Predicts Impending DOJ Indictment Against Binance Date: 12.06.23

  • admin
  • June 12, 2023
European Consumer Organization
Read More
  • News
  • Crypto

European Consumer Organization Calls for Stricter Regulation of Crypto Promotion on Social Media Platforms – Date: 12.06.23

  • admin
  • June 12, 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts
  • Eicher Motors shares surged following Jefferies’ bullish outlook and upgraded target price.
  • The USD/THB faces some side-line trading in the near term (UOB).
  • The euro extends its decline to fresh six-month lows near 1.0570
  • Bitcoin miners strategize for survival amid rising costs and upcoming halving
  • Awareness of non-banks as an option is on the rise.
SniperFx
  • Home
  • About Us
  • Contact
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
Forex & Crypto Updates

Input your search keywords and press Enter.